Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 48Breast Neoplasms 8Neoplasms 4Leiomyoma 3Breast Neoplasms, Male 2Sexual Dysfunction, Physiological 1Prostate Adenocarcinoma 1Neoplasm Metastasis 1Myofibroma 1Breast Cancer Invasive 1Advanced Prostate Cancer 1Advanced Prostate Adenocarcinoma 1Adenocarcinoma 1

Interventions

Radiotherapy 2Radiation 2relugolix 1histrelin 1darolutamide 1bicalutamide 1acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 1Triptorelin Pamoate 1Salicylic Acid 1Radiation Dose Hypofractionation 1Neoadjuvant Therapy 1Leuprolide 1Goserelin 1Flutamide 1Buserelin 1Adjuvants, Pharmaceutic 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Prostate Adenocarcinoma × Leuprolide × Clear all
NCT05050084 2026-05-04

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NRG Oncology

Phase 3 Active not recruiting
2,050 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡